trending Market Intelligence /marketintelligence/en/news-insights/trending/4jIDDPPyCrhacO5JvIYaiQ2 content esgSubNav
In This List

AstraZeneca, Ionis heart disease drug advances into preclinical development

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


AstraZeneca, Ionis heart disease drug advances into preclinical development

Ionis Pharmaceuticals Inc. said it advanced its lead drug candidate, renamed AZD8233, into preclinical development.

The drug, developed under a strategic collaboration with AstraZeneca PLC, is designed to treat cardiovascular disease.

Ionis received a $25 million milestone payment from AstraZeneca following the development. Ionis is also eligible to receive up to $300 million in additional milestone payments as the drug advances in development, as well as royalties from the drug's sales.

AstraZeneca will be responsible for developing and commercializing AZD8233.